A biopharmaceutical company using its thin film freezing technology to develop and commercialize powder inhalants for the treatment of pulmonary diseases. It has the potential to improve the solubility of poorly water-soluble drugs and increase the pharmacokinetic effects to a level that allows for development and commercialization. The company is developing powder inhalants for asthma patients, invasive pulmonary aspergillosis patients, and lung transplant patients. Based in Delaware.